Problems of arthritic pain assume staggering proportion in India

ANKUR BHATTACHARYA

Kolkata, 23 January: As India is a home to a staggering 180 million arthritic patients and the number is steadily increasing, a Bengaluru based consumer healthcare unit today claimed to have innovated a unique joint pain reliever cream to effectively address a completer care for such intolerable pain.
Introducing the new product called ‘Jointflex’, a topical analgesic cream for joint pain, along with an oral Nicotine Replacement Therapy(NRT) called ‘Nixit’ in Eastern Indian market for the first time since successfully capturing huge Southern Indian market for both the products, Himava Nath,Business Head,India and South Asia of Bengaluru based ‘Strides Consumer’ said here this afternoon that in view of the seriousness of the problem,the Rs 3,000 crores worth of consumer healthcare market in the country was now poised to become a Rs 5,000 crore market within the next five years.
Our expansion into the new geographic sphere testifies the company’s vision to take the brand to every customer in India before making them available to several neighbouring countries like Bangladesh, Nepal and Bhutan, said Nath.
He said it was imperative for any brand to deliver a proven solution in order to achieve high customer confidence,and claimed that both the products were based on advanced formulations with extensive research to become very useful to customers and help them effectively to ease their pain to a great extent.
Asked about their company’s outlook in further popularising the brands, Nath said after receivining overwhelming success of both Jointflex and Nixit in South India, they were confident to notch up 35 to 40 per cent annual growth in business from 2020-21 itself.
About the share of business of the two new products separately, he told on the sidelines of a business meet, that while Jointflex,which aimed to become the second largest such health product in the joint pain segment by 2022, currently enjoyed about 20 per cent share of the Rs 3,000 crores worth of domestic market, Nixit in its own category aimed to become a Rs 500 crores business by 2024 from around Rs 150 crores now.

Ends